Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| Autologous Adipose-derived Stem Cells | RB-ADSC, CEREWiNT®, Astrostem |
Alzheimer's Disease (Phase 1/2) | Regeneration Biomedical, Inc. | Other | Other | |
| AVB-101 | Frontotemporal Dementia (Phase 1/2) | AviadoBio | Other | DNA/RNA-based | ||
| Bezisterim | NE3107, HE3286 |
Alzheimer's Disease (Phase 3), Parkinson's Disease (Phase 1/2) | BioVie Pharma | Inflammation, Other | Small Molecule | |
| CDNF | cerebral dopamine neurotrophic factor | Parkinson's Disease (Phase 1/2) | Herantis Pharma Plc, Renishaw plc. | Other | Procedural Intervention, Other | |
| Dapagliflozin | Farxiga, Forxiga, BMS 512148 |
Alzheimer's Disease (Phase 1/2) | AstraZeneca, Bristol-Myers Squibb | Other | Small Molecule | |
| Dasatinib + Quercetin | Alzheimer's Disease (Phase 1/2) | Tau, Other | Combination, Small Molecule, Supplement, Dietary | |||
| DNL593 | PTV:PGRN, TAK-594 |
Frontotemporal Dementia (Phase 1/2) | Denali Therapeutics Inc., Takeda Pharmaceutical Company | Other | Other | |
| Emrusolmin | Anle138b, TEV-56286 |
Parkinson's Disease (Phase 1/2), Multiple System Atrophy (Phase 2) | MODAG GmbH, Teva | Tau, alpha-synuclein, Other | Small Molecule | |
| LY3884961 | PR001, PR001A |
Parkinson's Disease (Phase 1/2) | Eli Lilly & Co., Prevail Therapeutics | Other | DNA/RNA-based | |
| LY3884963 | PR006 | Frontotemporal Dementia (Phase 1/2) | Eli Lilly & Co., Prevail Therapeutics | Other | DNA/RNA-based | |
| Nicotinamide Riboside | Niagen, NR, Nicotinamide, Vitamin B3 |
Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 2), Mild Cognitive Impairment (Phase 1/2) | ChromaDex, Others | Other | Supplement, Dietary | |
| PBFT02 | Frontotemporal Dementia (Phase 1/2) | Passage Bio | Other | DNA/RNA-based |